BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX(NASDAQ:BCRX) RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 36,700 shares, and restricted stock units (RSUs) covering an aggregate of 71,400 shares, of BioCryst common stock. The options and RSUs were granted as of September 2, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
BioCryst to Present at Upcoming Investor Conference
BCRXRESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on Thursday, September 4, 2025, at 9:45 a.m. ET.
BioCryst Announces Departure of Dr. Helen Thackray
BCRXRESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an advisory role through the end of the year.
Barco Unveils HDR by Barco Slate through 2025 and U.S. Expansion Plans
BCRXRollout expands partnerships with Regal Cinemas and Alamo Drafthouse as overall domestic footprint grows rapidly LOS ANGELES, June 17, 2025 /PRNewswire/ -- Barco, the global leader in laser cinema, announced today the HDR by Barco slate through the end of 2025 alongside U.S. rollout plans...
Netherlands Approves BioCryst Pharma's ORLADEYO For Hereditary Angioedema Prevention, Expanding National Access Across Europe
BCRXBioCryst To Present New ORLADEYO Data At 2025 EAACI Meeting, Highlighting HAE Prophylaxis In Adults and Children
BCRXBiocryst Pharmaceuticals Announced New Data Which Highlights The Reduction In The Percentage Of Days With Hereditary Angioedema (HAE) Symptoms Among Young Children Initiating Berotralstat In The Apex-P Trial, And The Broad Safety And Efficacy Outcomes Obs
BCRXBioCryst Pharma Presents New Real-World Evidence Showing ORLADEYO Delivers Sustained HAE Attack Reduction in Adolescents & Severe Cases
BCRXBioCryst Announces FDA Acceptance Of Its New Drug Application For Oral, Once Daily ORLADEYO In Hereditary Angioedema Patents Aged 2 To 11 Years
BCRXRBC Capital Reiterates Outperform on BioCryst Pharma, Raises Price Target to $13
BCRXJP Morgan Maintains Overweight on BioCryst Pharma, Raises Price Target to $13
BCRXHC Wainwright & Co. Reiterates Buy on BioCryst Pharma, Maintains $30 Price Target
BCRXNeedham Maintains Buy on BioCryst Pharma, Raises Price Target to $17
BCRXBioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors
BCRXBioCryst posted $134.2 million in Q1 revenue, raised 2025 Orladeyo guidance, and now expects full-year profitability and positive cash flow.
Crude Oil Falls Over 2%; ISM Services PMI Rises In April
BCRXBioCryst Pharma Q1 Sales $145.53M Beat $126.87M Estimate
BCRXBioCryst Grants 48,000 RSUs To New Hires As Employment Inducement Under Nasdaq Rule
BCRXCantor Fitzgerald Initiates Coverage On BioCryst Pharma with Overweight Rating, Announces Price Target of $20
BCRXRBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $11 Price Target
BCRXNeedham Reiterates Buy on BioCryst Pharma, Maintains $15 Price Target
BCRXBioCryst Pharmaceuticals' CFO Anthony Doyle Notified The Company Of His Intention To Resign From His Employment With The Company, Effective April 9, 2025
BCRXCitizens Capital Markets Reiterates Market Outperform on BioCryst Pharma, Maintains $18 Price Target
BCRXRBC Capital Reiterates Outperform on BioCryst Pharma, Raises Price Target to $11
BCRXCitizens Capital Markets Reiterates Market Outperform on BioCryst Pharma, Maintains $18 Price Target
BCRXHC Wainwright & Co. Reiterates Buy on BioCryst Pharma, Maintains $30 Price Target
BCRXBioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings
BCRXBioCryst's Orladeyo showed sustained HAE attack reductions in real-world data. The company expects positive EPS and cash flow in the second half of 2025.
Biocryst Pharmaceuticals Expects To Approach Quarterly Positive EPS And Positive Cash Flow In The Second Half Of 2025, And To Be Profitable On An EPS Basis, With Positive Cash Flow, For Full Year 2026
BCRXBioCryst Pharmaceuticals Expects Full Year 2025 Total Revenue Of $560M-$575M Compared To Prior Guidance Of $540M-$560M And Consensus Of 545.31M, The Company Increased Its 2025 Outlook For Global Net Orladeyo Revenue To Between $535M-$550M, Previously $515
BCRXBioCryst Pharma Q4 2024 Adj EPS $(0.13) Misses $(0.06) Estimate, Sales $131.53M Beat $130.15M Estimate
BCRXBioCryst Pharmaceuticals Announced Results From An Interim Analysis Of The Ongoing Apex-p Clinical Trial Evaluating An Oral Granule Formulation Of Once-daily Orladeyo (Berotralstat) In Pediatric Patients With Hereditary Angioedema Aged 2 To <12 Years
BCRXBiocryst PharmaceuticalsS ays Infarmed In Portugal Has Recommended ORLADEYO (Berotralstat) For The Routine Prevention Of Recurrent Attacks Of Hereditary Angioedema In Eligible Patients 12 Years And Older
BCRXEvercore ISI Group Maintains Outperform on BioCryst Pharma, Raises Price Target to $12
BCRXNeedham Maintains Buy on BioCryst Pharma, Raises Price Target to $15
BCRXBioCryst Says ORLADEYO Net Revenue Expected Between $515M-$535M In 2025, Total revenue (Including RAPIVAB) Will Be $540M-$560M
BCRXBioCryst's ORLADEYO Gets Ireland's Approval: Expanding Access to Once-Daily HAE Therapy
BCRXRBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $10 Price Target
BCRXNeedham Reiterates Buy on BioCryst Pharma, Maintains $14 Price Target
BCRXBarclays Maintains Equal-Weight on BioCryst Pharma, Raises Price Target to $8
BCRX12 Health Care Stocks Moving In Monday's Intraday Session
BCRXBioCryst Adjusts ORLADEYO Revenue Guidance To $430M-$435M, Sees Total Product Revenue Of $443M-$448M
BCRXBioCryst Pharma Q3 2024 GAAP EPS $(0.07) Misses $(0.06) Estimate, Sales $117.085M Beat $112.503M Estimate
BCRXWatching Bird Flu-Related Stocks Following Report 'U.S. reports its first human case of H5 bird flu': BioCryst, NanoViricides, iBio, Inovio
BCRX